3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 1/2
6
Phase 1
3
Phase 4
2
Phase 3
1
Phase 2/3
1
Status
Active not recruiting
3
Completed
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Neoplasms by Site
1
Neoplasms
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Carcinoma, Transitional Cell
1
Interventions
Carboplatin
98
Cisplatin
95
pembrolizumab
90
Gemcitabine
81
Paclitaxel
80
Docetaxel
73
Capecitabine
64
Oxaliplatin
53
Specimen Handling
52
Fluorouracil
52
Magnetic Resonance Spectroscopy
50
Bevacizumab
49
Radiotherapy
48
Dexamethasone
45
Cyclophosphamide
44
Leucovorin
39
Drug Therapy
39
Irinotecan
37
Doxorubicin
36
Pemetrexed
35
Injections
30
Trastuzumab
28
Vincristine
27
Rituximab
27
Radiosurgery
25
Prednisone
25
Etoposide
25
130-nm albumin-bound paclitaxel
25
Radiation
24
Letrozole
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
enfortumab vedotin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled